Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics
- PMID: 24889915
- DOI: 10.1016/j.ejca.2014.04.014
Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics
Abstract
Most anticancer drugs are characterised by a steep dose-response relationship and narrow therapeutic window. Inter-individual pharmacokinetic (PK) variability is often substantial. The most relevant PK parameter for cytotoxic drugs is the area under the plasma concentration versus time curve (AUC). Thus it is somewhat surprising that therapeutic drug monitoring (TDM) is still uncommon for the majority of agents. Goals of the review were to assess the rationale for more widely used TDM of cytotoxics in oncology. There are several reasons why TDM has never been fully implemented into daily oncology practice. These include difficulties in establishing appropriate concentration target ranges, common use of combination chemotherapies for many tumour types, analytical challenges with prodrugs, intracellular compounds, the paucity of published data from pharmacological trials and 'Day1 = Day21' administration schedules. There are some specific situations for which these limitations are overcome, including high dose methotrexate, 5-fluorouracil infusion, mitotane and some high dose chemotherapy regimens. TDM in paediatric oncology represents an important challenge. Established TDM approaches includes the widely used anticancer agents carboplatin, busulfan and methotrexate, with 13-cis-retinoic acid also recently of interest. Considerable effort should be made to better define concentration-effect relationships and to utilise tools such as population PK/PD models and comparative randomised trials of classic dosing versus pharmacokinetically guided adaptive dosing. There is an important heterogeneity among clinical practices and a strong need to promote TDM guidelines among the oncological community.
Keywords: 5-Fluorouracil; Busulfan; Chemotherapy; Cytotoxics; Methotrexate; Mitotane; Oncology; Paediatric oncology; Pharmacokinetics; Therapeutic drug monitoring.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Therapeutic drug monitoring in cancer--are we missing a trick?Eur J Cancer. 2014 Aug;50(12):2005-9. doi: 10.1016/j.ejca.2014.04.013. Epub 2014 May 27. Eur J Cancer. 2014. PMID: 24878063
-
Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.Eur J Cancer. 2014 Aug;50(12):2020-36. doi: 10.1016/j.ejca.2014.04.015. Epub 2014 Jun 10. Eur J Cancer. 2014. PMID: 24928190 Review.
-
Target concentration intervention in oncology: where are we at?Ther Drug Monit. 2012 Jun;34(3):257-65. doi: 10.1097/FTD.0b013e3182557342. Ther Drug Monit. 2012. PMID: 22585183 Review.
-
Therapeutic drug monitoring of cancer chemotherapy.J Oncol Pharm Pract. 2007 Dec;13(4):207-21. doi: 10.1177/1078155207081133. J Oncol Pharm Pract. 2007. PMID: 18045780 Review.
-
Therapeutic drug monitoring in cancer chemotherapy.Bioanalysis. 2010 May;2(5):863-79. doi: 10.4155/bio.10.48. Bioanalysis. 2010. PMID: 21083218 Review.
Cited by
-
Population Pharmacokinetics in Oncology and Its Clinical Applications.Pharmaceutics. 2024 May 25;16(6):711. doi: 10.3390/pharmaceutics16060711. Pharmaceutics. 2024. PMID: 38931835 Free PMC article.
-
Microbiota as a mediator of cancer progression and therapy.Transl Res. 2017 Jan;179:139-154. doi: 10.1016/j.trsl.2016.07.021. Epub 2016 Aug 3. Transl Res. 2017. PMID: 27554797 Free PMC article. Review.
-
A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: The role of therapeutic drug monitoring.Medicine (Baltimore). 2020 Oct 2;99(40):e22620. doi: 10.1097/MD.0000000000022620. Medicine (Baltimore). 2020. PMID: 33019484 Free PMC article.
-
Tailoring structural properties of spray-dried methotrexate-loaded poly (lactic acid)/poloxamer microparticle blends.J Mater Sci Mater Med. 2019 Jan 8;30(1):12. doi: 10.1007/s10856-018-6214-6. J Mater Sci Mater Med. 2019. PMID: 30617752
-
5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.Oncotarget. 2018 Jan 30;9(14):11559-11571. doi: 10.18632/oncotarget.24338. eCollection 2018 Feb 20. Oncotarget. 2018. PMID: 29545919 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources